# Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

> **NCT00003427** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 36 (estimated)

## Conditions studied

- Anal Cancer
- Colorectal Cancer
- Esophageal Cancer
- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Gastric Cancer
- Gastrointestinal Carcinoid Tumor
- Liver Cancer
- Pancreatic Cancer
- Small Intestine Cancer

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00003427
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 2002-04
- **Final completion:** 2002-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2013-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003427, "Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00003427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*